About Invent Bio-Med Private Limited
Data last updated: 11 January 2026
Invent Bio-Med Private Limited is a private limited company based in Goregaon West, Maharashtra, India. It specialises in medical and laboratory equipment, a part of the broader healthcare sector. Incorporated on 03 May 2005, the company has been in operation for over 21 years.
Registered with ROC Mumbai under CIN U33110MH2005PTC152988.
Capital: an authorised share capital of ₹30 Cr and a paid-up capital of ₹24.7 Cr. It is led by directors including Rajkumar Gopilal Manglunia and Amit Banwarilal Agrawal.
Last AGM: 29 September 2025. Financial statements filed for year ended 31 March 2025. Office: Goregaon West, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹20.39 Cr, a growth of 37% compared to the previous year.
The company has a workforce of approximately 15 employees as per the latest available data.
The company is associated with 2 brands - Invent Bio, Invent Biomed. As per MCA filings, the company has open charges of ₹8.5 Cr and satisfied charges of ₹25.08 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website inventbiomed.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address24 1St Floor Piramal Industrial Estate, Bldg No – 4 Piramal Nagar S.V. Road Goregaon (West) Mumbai – 400104, Goregaon West, Maharashtra, India – 400104
-
IndustryHealthcare, Medical & Laboratory Equipment
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Invent Bio-Med Private Limited
Invent Bio-Med Private Limited operates two associated brands: Invent Bio and Invent Biomed. These brands represent Invent Bio-Med Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Provides a portfolio of interventional cardiovascular medical devices. | inventbio-med.com | |
| Manufacturer of drug eluting stents, PTCA balloon catheters, and vascular accessories | inventbiomed.com |
Competitors & Alternatives of Invent Bio-Med Private Limited
Brands and companies operating in the same space as Invent Bio-Med Private Limited include Silk Road Medical, Lifetech Scientific Corporation, InterShunt Technologies and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Silk Road Medical
|
Provider of neuroprotection devices for carotid artery disease | Sunnyvale, United States, United States | 2007 |
Lifetech Scientific Corporation
|
Interventional devices for cardiovascular and vascular diseases are developed. | Shenzhen, China, China | 1999 |
InterShunt Technologies
|
Cardiac catheters for cardiac disease treatment are developed. | Louisiana, United States, United States | 2015 |
Supira Medical
|
Developer of ventricular assist devices for coronary intervention and cardiogenic shock | Campbell, United States, United States | 2016 |
AVS Pulse
|
Pulsatile intravascular lithotripsy is developed for calcified arterial disease treatment. | Ann Arbor, United States, United States | 2017 |
Shanghai Baixin'an Biotechnology
|
A bioabsorbable coronary rapamycin-eluting stent system is developed using PLLA. | Pudong, China, China | 2014 |
Protaryx Medical
|
Protaryx Medical is focused on developing transseptal access devices. | Baltimore, United States, United States | 2019 |
Medinol
|
Thin cobalt-chrome stents are developed for coronary cardiovascular treatment. | Tel Aviv, Israel, Israel | 1992 |
S4 Medical
|
Catheter ablation treatments for atrial fibrillation are developed. | Columbus, United States, United States | 2017 |
HDL Therapeutics
|
Therapy to reverse coronary atherosclerosis is developed using patient plasma. | Short Hills, United States, United States | 2010 |
Business Activity of Invent Bio-Med Private Limited
Invent Bio-Med Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C13 | Other manufacturing including jewellery, musical instruments, medical instruments, sports goods, etc. activities | ********* |
Auditor Details of Invent Bio-Med Private Limited
Invent Bio-Med Private Limited is audited by Mandhania & Associates for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Mandhania & Associates | blur-value | blur-value | blur-value |
Board of Directors of Invent Bio-Med Private Limited
Invent Bio-Med Private Limited is currently managed by 5 directors, with 9 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rajkumar Gopilal Manglunia
Also directs:
Mohini Organics Private Limited
|
Director | 08 Aug 2017 | 8 Years 11 Months | Current |
| Amit Banwarilal Agrawal | Director | 16 May 2022 | 4 Years 1 Months | Current |
|
Ronak Manglunia
Also directs:
Rajal Bindal Multisolutions Private Limited
|
Director | 08 Aug 2017 | 8 Years 11 Months | Current |
| Shyam Manglunia | Director | 08 Aug 2017 | 8 Years 11 Months | Current |
Financials of Invent Bio-Med Private Limited FY 2025 filings available
Invent Bio-Med Private Limited reported revenue of ₹20.39 Cr (up 37% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Invent Bio-Med Private Limited
As of FY 2023, Invent Bio-Med Private Limited's shareholding pattern shows 43.10% by promoters, 56.90% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Invent Bio-Med Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Sep 2025 | Others | ₹8.5 Cr | Open |
| 12 Jun 2012 | Punjab National Bank | ₹9.1 Cr | Satisfied |
| 27 Jan 2012 | Small Industries Development Bank of India | ₹35 Lakh | Satisfied |
| 07 Jul 2011 | Punjab National Bank | ₹7.23 Cr | Satisfied |
| 26 Mar 2008 | Punjab National Bank | ₹6.3 Cr | Satisfied |
Total charge records: 7 View all charges
Employees and EPFO Compliance at Invent Bio-Med Private Limited
Invent Bio-Med Private Limited has a workforce of 15 employees as of Apr 06, 2024.
Employee Count & EPFO Data of Invent Bio-Med Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Invent Bio-Med Private Limited
GSTIN & GST Filing Data of Invent Bio-Med Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Invent Bio-Med Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Invent Bio-Med Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Invent Bio-Med Private Limited
MSME Payment Delays by Invent Bio-Med Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Invent Bio-Med Private Limited
Subsidiaries & Group Companies of Invent Bio-Med Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Invent Bio-Med Private Limited with ownership details.
MCA Filings & Documents of Invent Bio-Med Private Limited
MCA Filings & Documents of Invent Bio-Med Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Invent Bio-Med Private Limited
Frequently Asked Questions about Invent Bio-Med Private Limited
Invent Bio-Med Private Limited is an active private limited company in the healthcare sector based in Goregaon West, Maharashtra, India. It was incorporated on 03 May 2005 (21+ years old) and is registered under CIN U33110MH2005PTC152988. The company has 15 employees.
Invent Bio-Med Private Limited reported revenue of ₹20.39 Cr for FY 2025 (up 37.00% YoY).
The current directors of Invent Bio-Med Private Limited are:
The primary industry of Invent Bio-Med Private Limited is healthcare. The company specifically operates in medical and laboratory equipment. The company is currently active in this sector.
Invent Bio-Med Private Limited can be reached at the registered office: 24 1St Floor Piramal Industrial Estate, Bldg No – 4 Piramal Nagar S.V. Road Goregaon West Mumbai – 400104, Goregaon West, Maharashtra, India – 400104, or through the website inventbiomed.com.
The authorised capital is ₹30 Cr, and the paid-up capital is ₹24.7 Cr.